Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	6.92M 0 5.95M 5.61M 5.11M 9.56M 658M 9.6M 66.45M 25.68M 335M 25.99M 25.42M 1.06B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	6.92M 0 5.95M 5.61M 5.11M 9.56M 658M 9.6M 66.45M 25.68M 335M 25.99M 25.42M 1.06B	EV / Sales 2026 *	4.66x	EV / Sales 2027 *	2.66x
Free-Float	72.14%	Yield 2026 *	-	Yield 2027 *	-

09-04	Evogene Ltd. Approves Board Appointments	CI
08-28	L.I.A. Pure Capital Issues Response to Evogene	CI
08-25	Institutional Shareholder Services and Glass Lewis Makes Recommendations to Shareholders	CI
08-18	Evogene Ltd., Q2 2026 Earnings Call, Aug 18, 2026
08-18	Evogene Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-17	Freightos Names Yaron Eldad as Chief Financial Officer	MT
07-27	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
07-22	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
07-22	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
07-10	L.I.A. Pure Capital Sends Letter to Evogene	CI
07-08	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
06-24	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/07/21	Evogene : Aegis Capital Starts Evogene at Buy	MT
01/12/20	Evogene : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

08-31	Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward	PR
08-25	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees	PR
08-18	Evogene Reports Second Quarter and First Half 2026 Financial Results	PR
08-18	Evogene : Reports Second Quarter and First Half 2026 Financial Results	PU
08-18	Evogene: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	30/11/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	31/12/2021

Evogene Ltd Share Price TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation : Evogene Ltd

Latest news : Evogene Ltd

Last Transcript : Evogene Ltd

Analysts' recommendations : Evogene Ltd

Press Releases : Evogene Ltd

News in other languages : Evogene Ltd

Quotes and Performance

Managers and Directors : Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	02/06/2010
Sarit Firon CHM	Chairman	60	31/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	6.92M
LONZA GROUP AG	+0.65%	-6.91%	-2.66%	+11.21%	46.38B
REVOLUTION MEDICINES, INC.	+0.17%	-0.74%	+407.28%	+546.58%	44.51B
IQVIA HOLDINGS INC.	-0.86%	-2.60%	+35.51%	+20.35%	42.3B
BEONE MEDICINES AG	-0.14%	-2.98%	-0.04%	+82.21%	39.91B
CELLTRION, INC.	0.00%	-1.72%	+13.42%	+42.33%	32.79B
ASCENDIS PHARMA A/S	-3.44%	-2.43%	-	-	17.13B
MEDPACE HOLDINGS, INC.	-0.78%	-1.13%	+20.74%	+116.26%	16.36B
EUROFINS SCIENTIFIC SE	+0.59%	-2.86%	+13.38%	+31.71%	14.31B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.86%	-4.60%	+76.86%	+39.36%	13.29B
Average	-0.65%	-2.88%	+70.56%	+111.25%	29.66B
Weighted average by Cap.	-0.52%	-3.04%	+86.05%	+133.11%

	2026 *	2027 *
Net sales	1.48M 0 1.28M 1.2M 1.1M 2.05M 141M 2.06M 14.25M 5.51M 71.94M 5.57M 5.45M 228M	2.6M 0 2.24M 2.11M 1.92M 3.59M 247M 3.61M 24.97M 9.65M 126M 9.76M 9.55M 399M
Net income	-16.69M -0 -14.36M -13.52M -12.32M -23.05M -1.59B -23.14M -160M -61.93M -809M -62.66M -61.3M -2.56B	-13.92M -0 -11.97M -11.27M -10.27M -19.22M -1.32B -19.3M -134M -51.64M -675M -52.25M -51.12M -2.14B
Net Debt	-	-